G1 Therapeutics (GTHX) to Release Quarterly Earnings on Wednesday

G1 Therapeutics (NASDAQ:GTHX) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

G1 Therapeutics (NASDAQ:GTHX) last announced its earnings results on Wednesday, February 28th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.06. G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. The business had revenue of $14.87 million for the quarter, compared to the consensus estimate of $12.83 million. During the same period in the previous year, the business earned ($0.73) EPS. On average, analysts expect G1 Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

G1 Therapeutics Trading Up 3.4 %

GTHX stock opened at $3.99 on Monday. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.87 and a quick ratio of 3.45. The stock has a market capitalization of $208.40 million, a price-to-earnings ratio of -4.20 and a beta of 1.73. The business has a fifty day moving average price of $3.75 and a 200 day moving average price of $3.00. G1 Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $5.00.

Analysts Set New Price Targets

A number of brokerages have commented on GTHX. Needham & Company LLC reissued a “buy” rating and set a $12.00 price objective on shares of G1 Therapeutics in a report on Friday, April 12th. Wedbush reaffirmed an “outperform” rating and set a $5.00 price objective (up previously from $4.00) on shares of G1 Therapeutics in a report on Wednesday, February 28th.

Insider Transactions at G1 Therapeutics

In related news, insider Rajesh Malik sold 28,600 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $4.62, for a total value of $132,132.00. Following the transaction, the insider now directly owns 169,938 shares in the company, valued at $785,113.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.23% of the stock is owned by corporate insiders.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.